I keep buying Eli Lilly (NYSE:LLY), and the latest quarter just made it harder to stop. This is a confession of conviction. I have been adding through every dip in 2026, and the most recent earnings report told me the thesis is accelerating. What pulls me back to the buy button is simple. Lilly sits … This Pharma Stock Keeps Earning My Money, Here’s Why
Our editorial team includes several staff writers, each contributing their specialized knowledge to enhance the depth and breadth of our event and story coverage.